Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Total saponins from rubus parvifolius are a purified extract of saponin compounds derived from the roots of *Rubus parvifolius* L., a plant used in traditional Chinese medicine. These saponins have shown both antitumor and neuroprotective activities in preclinical studies. In cancer models, total saponins from rubus parvifolius inhibit proliferation and induce apoptosis in human chronic myeloid leukemia cells via activation of AMPK and JNK signaling pathways and inhibition of the STAT3 pathway. In cerebral ischemia models, they protect against ischemia/reperfusion injury by decreasing neuronal apoptosis, upregulating anti-apoptotic factor Bcl-2, and downregulating pro-apoptotic factor Bax. Their mechanism is thus primarily through modulation of apoptosis-related signaling cascades. No evidence for commercial development or branding; studies have been conducted primarily by academic institutions in China[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on total saponins from rubus parvifolius.